Abstract:Plain English summaryCystic fibrosis (CF) is the commonest life-limiting inherited disorder in the UK. It affects many parts of the body including the lungs and gut leading to increased infection and problems digesting food. People with CF need to undergo many treatments each day throughout their whole lives. These include tablets, inhalers and breathing exercises, which are a huge burden, taking up several hours every dayIt is therefore, really important that the treatments we give are supported by good evidence, usually gathered from clinical trials. Unfortunately, we do not have good evidence for many of the CF treatments. We recently ran an exercise known as a James Lind Alliance Priority Setting Partnership (JLA PSP) to find out which the CF community feel are the top priority research questions. People with CF and those who look after them suggested questions to be answered by clinical trials. Through a series of online surveys and workshops these were then shortlisted to give a final top ten.Due to infection risk people with CF are advised not to mix, this meant we had to do things differently to the usual way JLA PSPs are carried out. We used videoconferencing to enable multiple people with CF to participate. Surveys were accessible online and promoted through social media.AbstractBackgroundThe James Lind Alliance (JLA) method is well recognised for setting research priorities. The JLA approach involves a combination of surveys and workshop interactions between patients, carers and health care professionals to identify and agree on a “top ten” list of research questions. Respiratory infection is one of the hallmarks of cystic fibrosis (CF). To avoid cross infection, patients are advised not to meet face to face, preventing us following standard JLA methodology. Here we describe adaptations made during our recent JLA Priority Setting Partnership (PSP) in CF.MethodsWe elicited and prioritised research questions, using sequential online surveys, promoted through social media. People with CF participated in steering committee meetings and the final workshop, using videoconferencing. Alterations to workshop methodology enabled participants attending in person and those joining remotely, to contribute equally. We also altered the JLA methodology to include “lone” questions, asked by only one survey respondent. We are now working with the CF community to co-produce research projects that answer these top ten.ResultsThere were 482 respondents, from 23 countries, who submitted 1080 questions. Increases in the number of responses occurred just after promotion on social media. Use of videoconferencing enabled participation of multiple people with CF and ensured participation from anywhere in the world, including hospital inpatients. Inclusion of lone questions resulted in one being included in our top ten.ConclusionsThere is no “one-size-fits-all” for patient involvement methodologies. Through altering the JLA methods to fit our patient group we achieved wide participation. We believe that methods used in our project may also be applied to future partnerships to increase participation, especially where people may be hospitalised or be unable to travel. The methodology we are developing through the JLA PSP CF2 project may be useful for other PSPs to follow.

Research priorities for progressive pulmonary fibrosis in the UK

Progressive pulmonary fibrosis: an expert group consensus statement

Holistic management of patients with progressive pulmonary fibrosis

Good health for patients with PPF: Insights from patient-led international focus groups

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey

Research priorities for future pulmonary hypertension research: a James Lind Alliance priority setting partnership

Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

A roadmap to precision treatments for familial pulmonary fibrosis

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers

Priorities and barriers for research related to primary ciliary dyskinesia

Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures

The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

Involving patients and families in prioritising research in cardiomyopathies

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?

Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Evidence from recent clinical trials in fibrotic interstitial lung diseases